Tuberous sclerosis complex: Tumors and tumorigenesis

International Journal of Dermatology

Volumn 50, Issue 1, 2011, Pages 13-20

  Borkowska, Julita ^a   Schwartz, Robert A ^b   Kotulska, Katarzyna ^a   Jozwiak, Sergiusz ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOMYOLIPOMA; ASTROCYTOMA CELL; AUTOSOMAL DOMINANT DISORDER; BRAIN TUMOR; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ECHOGRAPHY; ELECTROENCEPHALOGRAPHY; HAMARTOMA; HEART TUMOR; HEMANGIOFIBROMA; HUMAN; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; LYMPHANGIOLEIOMYOMATOSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; REVIEW; RHABDOMYOMA; SUBEPENDYMOMA; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX;

ANGIOMYOLIPOMA; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HEART NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MALE; MUTATION; RHABDOMYOMA; SIROLIMUS; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 78650585145     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04727.x     Document Type: Review

References (55)

1. Józwiak S, Schwartz RA, Janniger CK, et al. Skin lesions in children with tuberous sclerosis complex: their incidence, natural course and diagnostic significance. Int J Dermatol 1998; 37: 911-917.
2. Jozwiak S, Migone N, Ruggieri M. The tuberous sclerosis complex. Phakomatoses and hamartoneoplastic syndromes. In: Ruggieri M, Pascual Castroviejo I, Di Rocco C, eds. Neurocutaneous Disorders. Vienna: Springer, 2008: 181-227.
3. Ahlsén G, Gillberg IC, Lindblom R, Gilberg C. Tuberous sclerosis in western Sweden. A population study of cases with early childhood onset. Arch Neurol 1994; 51: 76-81.
4. Schwartz RA, Fernandez G, Kotulska K, Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics and management. J Am Acad Dermatol 2007; 57: 189-202.
5. Roach ES, Gomez MR, Northrup H. Tuberous Sclerosis Consensus Conference: revised clinical diagnostic criteria. J Child Neurol 1998; 13: 624-628.
6. Jozwiak S, Schwartz RA, Janniger CK, Bielicka-Cymerman J. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol 2000; 15: 652-659.
7. Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001; 68: 64-80.
8. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ. Molecular genetic advances in tuberous sclerosis. Hum Genet 2000; 107: 97-114.
9. Kwiatkowski DJ, Manning BD. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 2005; 14: 251-258.
10. Zhang H, Cicchetti G, Onda H, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts P13K-Akt signaling through downregulation of PDGFR. J Clin Invest 2003; 112: 1223-1233.
11. Jozwiak J, Jozwiak S, Wlodarski P. Possible mechanisms of disease development in tuberous sclerosis. Lancet Oncol 2008; 9: 73-79.
12. Rosner M, Freilinger A, Hengstschläger M. The tuberous sclerosis genes and regulation of the cyclin-dependent kinase inhibitor p27. Mutat Res 2006; 613: 10-16.
13. Freilinger A, Rosner M, Krupitza G, et al. Tuberin activates the proapoptotic molecule BAD. Oncogene 2006; 25: 6467-6479.
14. Nie D, Di Nardo A, Han JM, et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13: 163-172.
15. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ. Loss of TSC1 or TSC2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003; 63: 5173-5177.
16. Mizuguchi M, Mori M, Nozaki Y, et al. Absence of allelic loss in cytomegalic neurons of cortical tuber in the Eker rat model of tuberous sclerosis. Acta Neuropathol 2004; 107: 47-52.
17. Rakowski SK, Winterkom EB, Paul E, et al. Renal manifestations of tuberous sclerosis complex: incidence, prognosis and predictive factors. Kidney Int 2006; 70: 1777-1782.
18. Baskin HJ Jr. The pathogenesis and imaging of the tuberous sclerosis complex. Pediatr Radiol 2008; 38: 936-952.
19. Tyburczy ME, Kotulska K, Pokarowski P, et al. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Am J Pathol 2010; 176: 1878-1890.
20. Rok P, Kasprzyk-Obara J, Domanska-Pakiela D, Jozwiak S. Clinical symptoms of tuberous sclerosis complex in patients with an identical TSC2 mutation. Med Sci Monit 2005; 11: 230-234.
21. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372: 657-668.
22. Barkovich AJ, Kuzniecky RI, Jackson GD, et al. A developmental and genetic classification for malformations of cortical development. Neurology 2005; 65: 1873-1887.
23. Khanna PC, Godinho S, Pungavkar SA, Patkar DP. Ultrafast MRI in the prenatal diagnosis of Bourneville's tuberous sclerosis. Neurol India 2005; 53: 349-350.
24. Curatolo P, Cusmai R, Cortesi F, et al. Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci 1991; 615: 8-16.
25. Jambaque I, Cusmai R, Curatolo P. Neuropsychological aspects of tuberous sclerosis in relation to epilepsy and MRI findings. Dev Med Child Neurol 1991; 33: 698-705.
26. Doherty C, Goh S, Young Poussaint T, et al. Prognostic significance of tuber count and location in tuberous sclerosis complex. J Child Neurol 2005; 20: 837-841.
27. Raznahan A, Higgins NP, Griffiths PD, et al. Biological markers of intellectual disability in tuberous sclerosis. Psychol Med 2007; 37: 1293-1304.
28. Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 2004; 63: 1236-1242.
29. Yates JRW. Tuberous sclerosis. Eur J Hum Genet 2006; 14: 1065-1073.
30. Ewalt DH, Diamond N, Rees C, et al. Longterm outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol 2005; 174: 1764-1766.
31. Henske EP. Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr Nephrol 2005; 20: 854-857.
32. Sampson JR. The kidney in tuberous sclerosis: manifestations and molecular genetic mechanisms. Nephrol Dial Transplant 1996; 11: 34-37.
33. Bjornssin J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological and genetic features. Am J Pathol 1996; 149: 1201-1208.
34. Hancock E, Osborne J. Lymphangoleiomyomatosis: a review of the literature. Respir Med 2002; 96: 1-6.
35. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP. Molecular pathogenesis of lymphangoleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2007; 36: 398-408.
36. Paramés F, Freitas I, Martins JD, et al. Cardiac tumors: the 17-year experience of pediatric cardiology department. Rev Port Cardiol 2009; 28: 929-940.
37. Jozwiak S, Kotulska K, Kasprzyk-Obara J, et al. Clinical and genotype studies of cardiac tumors in 154 patients with tuberous sclerosis complex. Pediatrics 2006; 118: 1146-1151.
38. Kotulska K, Larysz-Brysz M, Grajkowska W, et al. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities. Pediatr Dev Pathol 2009; 12: 89-96.
39. Borkowska J, Schwartz RA, Józwiak S. Recent perspectives on diagnosis and treatment of tuberous sclerosis complex in children. Int J Disability Hum Dev 2009; 8: 369-375.
40. Józwiak S, Schwartz RA. Dermatologic and stomatologic manifestations of tuberous sclerosis. In: Curatolo P, ed. Tuberous Sclerosis Complex: From Basic Science to Clinical Phenotypes. London: International Child Neurology Association/MacKeith Press, 2004: 136-169.
41. Schwartz RA, Józwiak S, Pedersen R. Tuberous sclerosis. [eMedicine Pediatrics.] 2010. [Accessed March 9 2010].
42. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007; 57: 1046-1050.
43. Kennerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker model rat of tuberous sclerosis complex. Pediatr Res 2005; 51: 67-75.
44. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
45. Wienecke R, Fackler I, Linsenmaier U, et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006; 48: e27-e29.
46. Herry I, Neukirch C, Debray MP, et al. Dramatic effect of sirolimus on renal angiomyolipomas in patients with tuberous sclerosis complex. Eur J Intern Med 2007; 18: 76-77.
47. Lam C, Bouffet E, Tabori U, et al. Rapamycin (sirolimus) in tuberous sclerosis-associated pediatric central nervous system tumors. Pediatr Blood Cancer 2010; 54: 476-479.
48. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
49. Muncy J, Butler IJ, Koenig MK. Rapamycin reduces seizure frequency in tuberous sclerosis complex. J Child Neurol 2009; 24: 477.
50. Zheng LH, Xu L, Gutman DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008; 63: 444-453.
51. Ljungberg MC, Sunnen CN, Lugo JN, et al. Rapamycin suppresses seizures and neuronal hyphertrophy in a mouse model of cortical dysplasia. Dis Model Mech 2009; 2: 389-398.
52. Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc (+/-) mouse model of tuberous sclerosis. Nat Med 2008; 14: 843-848.
53. Hofbauer GF, Marcollo-Pini A, Corsenca A, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008; 159: 473-475.
54. Rauktys A, Lee N, Lee L, Dabora S. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 2008; 8: 1-9.
55. Haemel AK, O'Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010; 146: 715-718.